Compare DSP & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSP | OABI |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.6M | 294.3M |
| IPO Year | 2021 | 2021 |
| Metric | DSP | OABI |
|---|---|---|
| Price | $13.62 | $4.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $17.81 | $4.50 |
| AVG Volume (30 Days) | 283.3K | ★ 2.1M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.14 | 6.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $344,201,000.00 | $18,666,000.00 |
| Revenue This Year | $20.27 | $52.42 |
| Revenue Next Year | $16.88 | $64.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $8.11 | $1.32 |
| 52 Week High | $14.80 | $5.43 |
| Indicator | DSP | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 57.35 | 69.68 |
| Support Level | $10.36 | $1.71 |
| Resistance Level | $13.36 | N/A |
| Average True Range (ATR) | 0.57 | 0.37 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 72.05 | 58.89 |
Viant Technology Inc is an advertising technology company engaged in providing a cloud-based demand-side platform (DSP) for programmatic advertising. The company enables marketers and advertising agencies to plan, buy, and measure digital advertising campaigns across multiple channels, including connected TV, streaming audio, mobile, desktop, and digital out-of-home. Its platform leverages data integrations and proprietary identity solutions to deliver targeted advertising, audience insights, and performance measurement.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.